Glusafe Tablet SR is a combination oral hypoglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 2 mg, Metformin 500 mg, and Pioglitazone 15 mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), thereby enhancing glucose uptake in adipose tissue and muscle. The sustained-release formulation ensures gradual drug release, promoting better patient compliance and stable plasma concentrations. Glusafe Tablet SR is indicated for adults inadequately controlled on diet and exercise alone or on monotherapy. It should be used with caution in patients with renal or hepatic impairment, heart failure, or a history of lactic acidosis. Common adverse effects may include gastrointestinal discomfort, hypoglycemia, weight gain, and edema. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Glusafe Tablet SR should be prescribed and administered under medical supervision to optimize therapeutic outcomes and minimize risks.